Cancer

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic…

2 years ago

Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K

CHICAGO, IL / ACCESSWIRE / April 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 years ago

Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection

Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce…

2 years ago

Sunshine Biopharma’s Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching…

2 years ago

Preliminary Results for the Year Ended 31 December 2023

19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the…

2 years ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market…

2 years ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market…

2 years ago

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented…

2 years ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company’s In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management…

2 years ago

Cantargia Publishes Annual Report for 2023

LUND, SE / ACCESSWIRE / April 18, 2024 / Cantargia (STO:CANTA)Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that the annual…

2 years ago